165 related articles for article (PubMed ID: 2127353)
1. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?].
Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R
Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353
[TBL] [Abstract][Full Text] [Related]
2. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of China-made recombinant streptokinase in acute myocardial infarction. Collaborative Study Group on Thrombolysis with China-made recombinant streptokinase.
Chin Med J (Engl); 1997 Jan; 110(1):50-2. PubMed ID: 9594322
[TBL] [Abstract][Full Text] [Related]
4. [Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients].
Jorge Sdo C
Arq Bras Cardiol; 1992 Jul; 59(1):23-30. PubMed ID: 1341143
[TBL] [Abstract][Full Text] [Related]
5. [A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial].
Steffensen R; Sandøe E
Ugeskr Laeger; 1991 Oct; 153(41):2880-3. PubMed ID: 1949301
[TBL] [Abstract][Full Text] [Related]
6. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
[TBL] [Abstract][Full Text] [Related]
7. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
8. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
[TBL] [Abstract][Full Text] [Related]
10. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
[TBL] [Abstract][Full Text] [Related]
11. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
Tsui W; Pierre K; Massel D
Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
[TBL] [Abstract][Full Text] [Related]
12. Hypotension in acute myocardial infarction patients given streptokinase.
Lateef F; Anantharaman V
Singapore Med J; 2000 Apr; 41(4):172-6. PubMed ID: 11063182
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
Lorenzoni R; Fattore G; Gensini G
G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
Chen B; Wang W; Zhao H; Hu D; Xu C; Zhao M; Lu M; Liu J; Wu C
Chin Med J (Engl); 2003 Jan; 116(1):142-4. PubMed ID: 12667408
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
16. [R-R variability in acute anterior infarct after thrombolytic therapy].
Boghossian SH; Maia IG; Costa Filho R; Alves PA
Arq Bras Cardiol; 1992 Nov; 59(5):365-8. PubMed ID: 1340735
[TBL] [Abstract][Full Text] [Related]
17. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
[TBL] [Abstract][Full Text] [Related]
18. [In-hospital survival predictors in infarction patients undergoing fibrinolytic therapy].
Nicolau JC; Pinto MA; Nogueira PR; Lorga AM; Jacob JL; Garzon SA
Arq Bras Cardiol; 1993 Sep; 61(3):143-8. PubMed ID: 8110042
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
Grines CL; Nissen SE; Booth DC; Gurley JC; Chelliah N; Wolf R; Blankenship J; Branco MC; Bennett K; DeMaria AN
Circulation; 1991 Aug; 84(2):540-9. PubMed ID: 1907228
[TBL] [Abstract][Full Text] [Related]
20. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
